An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
In the 2008 WHO classification, chronic myeloid malignancies that share both myelodysplastic and myeloproliferative features define the myelodysplastic/myeloproliferative group, which includes chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia, refractory anemia with ring sideroblasts and thrombocytosis, and myelodysplastic/myeloproliferative unclassified. With the notable exception of refractory anemia with ring sideroblasts and thrombocytosis, there is much overlap among the various subtypes at the molecular and clinical levels, and a better definition of these entities, an understanding of their biology and an identification of subtype-specific molecular or cellular markers are needed. To address some of these challenges, a panel comprised of laboratory and clinical experts in myelodysplastic/myeloproliferative was established, and four independent academic MDS/MPN workshops were held on: 9(th) March 2013, in Miami, Florida, USA; 6(th) December 2013, in New Orleans, Louisiana, USA; 13(th) June 2014 in Milan, Italy; and 5(th) December 2014 in San Francisco, USA. During these meetings, the current understanding of these malignancies and matters of biology, diagnosis and management were discussed. This perspective and the recommendations on molecular pathogenesis, diagnosis and clinical characterization for adult onset myelodysplastic/myeloproliferative is the result of a collaborative project endorsed and supported by the MDS Foundation.
Tufts University Medical Center, Boston, MA, USA tmughal911@hotmail.com.
Tariq I
TI
Mughal
Wessex Regional Genetics Laboratory, Salisbury, UK.
Nicholas C P
NC
Cross
H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Eric
E
Padron
Cleveland Clinic Taussig Cancer Institute, OH, USA.
Ramon V
RV
Tiu
Vanderbilt University Medical Center, Nashville, TN, USA.
Michael
M
Savona
University of Pavia Medical School, S. Matteo University Hospital, Pavia, Italy.
Luca
L
Malcovati
Mayo Clinic Cancer Center, Scottsdale, AZ, USA.
Raoul
R
Tibes
H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Rami S
RS
Komrokji
Hôpital Saint-Louis, Paris 7, France.
Jean-Jacques
JJ
Kiladjian
MD Anderson Cancer Center, Houston, TX, USA.
Guillermo
G
Garcia-Manero
Weill Cornell Medical College, New York, NY, USA.
Attilio
A
Orazi
Mayo Clinic Cancer Center, Scottsdale, AZ, USA.
Ruben
R
Mesa
Cleveland Clinic Taussig Cancer Institute, OH, USA.
Jaroslaw P
JP
Maciejewski
Hôpital Saint-Louis, Paris 7, France.
Pierre
P
Fenaux
Hôpital Saint-Louis, Paris 7, France.
Raphael
R
Itzykson
King's College Hospital, GKT School of Medicine, London, UK.
Ghulam
G
Mufti
Institut Gustave Roussy, Villejuif, France.
Eric
E
Solary
H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Alan F
AF
List
D000328:Adult; D005260:Female; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D006801:Humans; D008297:Male; D054437:Myelodysplastic-Myeloproliferative Diseases / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D017410:Practice Guidelines as Topic